Yes, there are well-established links between fascia and both POTS and hEDS
Fascia plays a central mechanistic role in both hEDS and POTS through altered connective tissue structure, reduced mechanical stiffness, and impaired fibroblast function—creating a pathophysiological cascade that contributes to vascular laxity, autonomic dysfunction, and the high co-occurrence of these conditions. 1, 2
The Fascia-hEDS Connection
The fascial abnormalities in hEDS are now recognized as fundamental to disease pathophysiology rather than incidental findings:
Skin biopsies demonstrate abnormal collagen fibril structure that triggers fibroblast dysfunction within connective tissue, leading to altered cellular adhesion and cytoskeletal responses 1
Connective tissue in hEDS is measurably softer and less stiff than in healthy controls—a critical parameter controlled by fascial microstructure 1
Recent molecular evidence reveals consistent fascial pathology including abnormal fascial thickness, impaired interfascial gliding, excessive myofibroblast activation, tendon elongation, and altered tissue stiffness 2
This emerging framework reframes hEDS as a disorder of pathological fascial remodeling, where dysregulated fascia directly contributes to the widespread multisystem symptoms characteristic of the condition 2.
The Fascia-POTS Link in hEDS
The connection between fascial abnormalities and POTS is mechanistically plausible and clinically significant:
Proposed Mechanisms
Vascular laxity from fascial dysfunction is theorized as a primary driver—the same connective tissue abnormalities affecting fascia also compromise vascular wall integrity, leading to excessive venous pooling and orthostatic intolerance 1
Additional contributing factors include:
- Peripheral neuropathy affecting autonomic regulation
- Emerging evidence of autoimmune etiologies 1
- Hypovolemic, neuropathic, or hyperadrenergic POTS phenotypes, all potentially influenced by underlying connective tissue pathology 1
Clinical Co-occurrence Data
The overlap between these conditions is substantial:
- 37.5% of hEDS/HSD patients have POTS in survey studies 1
- POTS prevalence in EDS ranges from 17.5% to 92.7% depending on the population studied 3
- EDS prevalence in POTS patients ranges from 17.9% to 50.0% 3
- POTS is significantly more prevalent in hEDS (48%) compared to HSD (23.5%), particularly in younger patients (<35 years: 58.3% in hEDS vs 29.6% in HSD) 4
Clinical Implications
Recognition and Testing
Clinicians should maintain high suspicion for POTS in patients with hEDS/HSD presenting with orthostatic symptoms, but universal screening is not warranted 1. Testing should be targeted to those with:
- Lightheadedness or dizziness upon standing
- Palpitations
- Presyncope or syncope
- Exercise intolerance
Important Caveats
The mechanistic basis remains incompletely understood and may be confounded by:
- Medications (stimulants, centrally acting agents) 1
- Deconditioning from chronic illness
- Many studies use inconsistent diagnostic criteria (not 2017 hEDS criteria) 1
The experimental evidence linking these biological mechanisms is limited and evolving 1. While theoretical explanations exist for how fascial pathology leads to POTS, robust data supporting these hypotheses remain inconsistent 1.
Management Considerations
Patients with both hEDS and POTS experience:
- Greater medication use and pain medication requirements 3
- More severe gastrointestinal symptoms 3
- Disability across all WHO life domains 5
- Symptoms that are particularly more pronounced with age in hEDS 4
POTS prevalence decreases with age in both hEDS and HSD, suggesting potential for symptom evolution or adaptation over time 4.
The fascia-centered framework offers an integrated model connecting molecular mechanisms with clinical expression, though much remains to be elucidated regarding specific therapeutic targets and personalized interventions 2.